Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
– Priority Review recognizes the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new t...
Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability ...
– The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-fr...
Over 24 weeks, a once-weekly subcutaneous injection of CT-388 achieved a clinically meaningful and statistically significant ...
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated nea...
Columvi, in combination with chemotherapy, demonstrated a statistically significant improvement in overall survival for peopl...
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2.1 Patients with HER2-low s...
Novartis reportedly plans to cut 680 development jobs worldwide, separate from an 8,000-employee restructuring, aiming to resha...
Roche introduces its suite of navify operational excellence solutions, including navify Analytics and navify Monitoring, for ...
